Literature DB >> 16484978

Assessing capacity for surveillance, prevention, and control of West Nile virus infection--United States, 1999 and 2004.

.   

Abstract

Indigenous human disease caused by West Nile virus (WNV) was first identified in the United States in August 1999 in the greater New York City area. By the end of 2004, human WNV disease had been reported in all states except Washington, Hawaii, and Alaska, and WNV transmission to humans had been documented by five routes: mosquito bites (principally from Culex spp.), blood transfusions, organ transplantation, transplacental transfer, and breastfeeding. During 1999-2005, a total of 19,525 cases of WNV disease in humans and 771 deaths were reported in the United States. In 2000, CDC first published guidelines for WNV surveillance, prevention, and control and created ArboNET, an electronic surveillance and reporting system. Beginning in 1999, WNV surveillance and prevention activities had been initiated in selected states and large cities through the CDC Epidemiology and Laboratory Capacity (ELC) cooperative agreements for emerging infectious diseases and subsequently expanded to all 50 states, six large cities/counties, and Puerto Rico. In 2005, to assess the capacity of state and large-city/county health departments to conduct WNV surveillance, prevention, and control activities, the Council of State and Territorial Epidemiologists (CSTE), with assistance from the Association of Public Health Laboratories (APHL) and CDC, surveyed WNV programs in the 50 states and six large-city/county health departments. This report describes the results of that assessment, which indicated that all participating states and cities had well-developed surveillance and control programs for human, avian, equine, or mosquito WNV.

Entities:  

Mesh:

Year:  2006        PMID: 16484978

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  8 in total

1.  Persistent infection with West Nile virus years after initial infection.

Authors:  Kristy Murray; Christopher Walker; Emily Herrington; Jessica A Lewis; Joseph McCormick; David W C Beasley; Robert B Tesh; Susan Fisher-Hoch
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

2.  Unforeseen costs of cutting mosquito surveillance budgets.

Authors:  Gonzalo M Vazquez-Prokopec; Luis F Chaves; Scott A Ritchie; Joe Davis; Uriel Kitron
Journal:  PLoS Negl Trop Dis       Date:  2010-10-26

3.  Findings of long-term depression up to 8 years post infection from West Nile virus.

Authors:  Melissa S Nolan; Anne M Hause; Kristy O Murray
Journal:  J Clin Psychol       Date:  2012-05-23

4.  Assessment of Arbovirus Surveillance 13 Years after Introduction of West Nile Virus, United States.

Authors:  James L Hadler; Dhara Patel; Roger S Nasci; Lyle R Petersen; James M Hughes; Kristy Bradley; Paul Etkind; Lilly Kan; Jeffrey Engel
Journal:  Emerg Infect Dis       Date:  2015-07       Impact factor: 6.883

5.  Long-term neurological outcomes in West Nile virus-infected patients: an observational study.

Authors:  Jill E Weatherhead; Vicki E Miller; Melissa N Garcia; Rodrigo Hasbun; Lucrecia Salazar; Mazen M Dimachkie; Kristy O Murray
Journal:  Am J Trop Med Hyg       Date:  2015-03-23       Impact factor: 2.345

6.  Perceptual influences on self-protective behavior for West Nile virus, a survey in Colorado, USA.

Authors:  Craig W Trumbo; Raquel Harper
Journal:  BMC Public Health       Date:  2015-06-18       Impact factor: 3.295

7.  Depression after infection with West Nile virus.

Authors:  Kristy O Murray; Melissa Resnick; Vicki Miller
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

8.  National capacity for surveillance, prevention, and control of West Nile virus and other arbovirus infections--United States, 2004 and 2012.

Authors:  James L Hadler; Dhara Patel; Kristy Bradley; James M Hughes; Carina Blackmore; Paul Etkind; Lilly Kan; Jane Getchell; James Blumenstock; Jeffrey Engel
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-04-04       Impact factor: 17.586

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.